JPMorgan Identifies Top EU Pharma, Biotech & Life Sciences Stocks Poised for 2026 Growth
Friday, March 13, 2026
JPMorgan's latest analysis positions the European pharmaceutical, biotechnology, and life sciences sector for substantial expansion in 2026, driven by robust pipelines, strategic collaborations, and improving market dynamics. Leading the rankings is AstraZeneca, anticipated to achieve best-in-sector low double-digit Core EPS growth, even amid challenges from Farxiga patent expiration. The company's pipeline holds approximately $12 billion in risk-adjusted peak sales potential from upcoming drug readouts. Projections indicate AstraZeneca reaching $80 billion in revenues by 2030, supported by recent regulatory milestones such as the U.S. FDA's priority review acceptance for its hypertension treatment baxdrostat. Morgan Stanley has also elevated its price target, underscoring sector-leading earnings growth.
In second place, Novartis is set for medium-term upgrades fueled by strong performances from Kisqali, Kesimpta, and Pluvicto, though tempered by Entresto generics. Four major pipeline readouts in 2026 could each trigger multi-billion dollar sales forecast revisions. Recent announcements include a $120 million upfront collaboration with Monte Rosa Therapeutics for immune-mediated diseases and a Buy rating reaffirmation from Deutsche Bank post-RNA deal. JPMorgan has upgraded Novartis to Overweight with a SFr125 price target.
Bayer ranks third, with enhancements in both Crop and Pharma divisions signaling strong 2027-2030 growth. Trading at a discounted 5x 2027E EV/EBITDA, the valuation appears increasingly attractive amid new product cycles and potential glyphosate litigation relief. European regulators have backed Bayer's menopause drug Lynkuet, advancing EU approval, while a multi-year extension with Ginkgo Bioworks bolsters biological product development for agriculture. Overweight rating with €50 target.
Among biotechs, Argenx stands out with 39% YoY revenue growth to $5.7 billion in 2026 from Vyvgart momentum and five registrational trials. UCB anticipates Bimzelx sales upgrades post-Hidradenitis Suppurativa launch, targeting €8,384 million revenues. Zealand Pharma features petrelintide Phase II data in obesity. In life sciences, Lonza expects 10-13% CDMO growth; Sartorius Group high-single-digit sales; and Bachem over 35% acceleration from Building K ramp-up. All carry Overweight ratings with specified targets.[1]
This outlook reflects broader European trends, including regulatory evolutions like the EU Pharma Package agreement, which adjusts data and market protections to eight years plus extensions up to 11 years, alongside obligations for pan-EU medicine availability. Proposals to simplify MDR/IVDR aim to cut administrative burdens via risk-based conformity assessments. The EU Biotech Act seeks to enhance competitiveness through streamlined processes, funding access, and incentives, impacting clinical trials, SoHO, and GMOs. These reforms balance innovation acceleration with safety, positioning Europe as a biotech hub.[2]
Swiss life sciences exemplify investor momentum, with Basel clusters drawing early-stage firms via BaseLaunch, which has facilitated over $1 billion in funding. Recent deals like DISCO-Amgen ($618M potential) and TECregen (CHF 10M) highlight AI and data focus, underscoring location's role in scaling innovations globally.[3]
For pharma executives, these insights inform **strategy** in R&D investments, partnerships, and supply chain resilience. Researchers and manufacturers should monitor pipeline catalysts, while regulators track compliance shifts. Biopharma innovators benefit from biotech act incentives, and technology providers eye AI integrations. This synthesis equips stakeholders for 2026's opportunities in **Biotechnology**, **Research & Development**, and **Strategy** categories.
